Evidence map›Paper›PMID 38748393›Full record

ArticleAnalytical sciences : the international journal of the Japan Society for Analytical Chemistry2024

In vitro evaluation of novel SN-38 prodrug activated by α-rhamnosidase of exogenous enzyme.

Teruki Nii, Shoichi Hijii, Ryosuke Kaneko, Kenta Tanito, Kota Yamanaka, Akihiro Kishimura, Takeshi Mori, Yoshiki Katayama

Abstract read
PubMed Publisher
In one paragraph

Article in Analytical sciences : the international journal of the Japan Society for Analytical Chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Teruki Nii *Graduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan. nii.teruki.204@m.kyushu-u.ac.jp.
Shoichi Hijii *Graduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan.
Ryosuke KanekoDepartment of Applied Chemistry, Faculty of Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fu-Kuoka, 819-0395, Japan.
Kenta TanitoGraduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan.
Kota YamanakaGraduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan.
Akihiro KishimuraGraduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan.
Takeshi MoriGraduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan.
Yoshiki KatayamaGraduate School of Systems Life Sciences, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan. katayama.yoshiki.958@m.kyushu-u.ac.jp.

Funding

Iketani Science and Technology Foundation No. 0361055-AJapan Society for the Promotion of Science London JP24K21087Terumo Foundation for Life Sciences and Arts No. 23-III2034Uehara Memorial Foundation No. 202310209
6 · The paper itself

Abstract

This study introduces the α-rhamnose (Rham)-conjugated prodrug of SN-38 (Rham-SN-38) as a promising alternative to irinotecan. α-rhamnosidase, responsible for SN-38 release from Rham-SN-38, does not express in human cells, minimizing individual variability and side effects. The injection of the α-rhamnosidase into the tumor tissues makes it possible, for the first time, to activate the Rham-SN-38. Furthermore, α-rhamnosidase demonstrates significantly higher activity than carboxylesterase, the specific enzyme activating irinotecan. SN-38 release mediated by α-rhamnosidase completes within 2 h, with a k

Indexed as

Glycoside HydrolasesIrinotecanProdrugsCell Line, TumorDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansalpha-L-rhamnosidaseGlycoside HydrolasesIrinotecanProdrugsCancerEnzyme prodrug therapyExogenous enzymeProdrug

Identifiers

PMID38748393

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.